Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parathyroid hormone - Takeda

Next Previous
Drug Profile

Parathyroid hormone - Takeda

Alternative Names: 423562; ALX 111; Natpar; Natpara; NPSP-795; NPSP558; Parathyroid hormone (1-84) - Takeda; PREOS; Preotact; PTH (1-84); PTH 1-84; Recombinant human parathyroid hormone-1-84; rhPTH (1-84); rhPTH-1-84; SB-423562; SHP-635; SHP634; TAK 834

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NPS Pharmaceuticals
  • Developer National Institutes of Health (USA); NPS Pharmaceuticals; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants; Parathyroid hormone receptor agonists; Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoparathyroidism; Postmenopausal osteoporosis
  • Phase II Hypocalcaemia; Hypothyroidism
  • Discontinued Osteoporosis

Most Recent Events

  • 06 Oct 2022 Takeda withdrew a phase III trial prior to enrolment due to business decision for Hypoparathyroidism in Japan (SC) (NCT03878953)
  • 31 Aug 2022 Takeda initiates a phase III trial for Hypoparathyroidism in Japan (SC) (NCT03878953)
  • 21 Apr 2022 Takeda completesa phase I trial of a new formulation of Parathyroid hormone in Healthy volunteers in USA (SC) (NCT05137730)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top